AB-506
Modify Date: 2024-01-27 18:39:41
AB-506 structure
|
Common Name | AB-506 | ||
|---|---|---|---|---|
| CAS Number | 2245020-50-0 | Molecular Weight | 461.854 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H18ClF2N5O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AB-506AB-506 is a small-molecule inhibitor targeting HBV core protein, inhibits viral replication in vitro (IC50=77 nM).AB-506 binds to HBV core protein, accelerates capsid assembly and inhibits HBV pgRNA encapsidation.AB-506 blocks cccDNA establishment in HBV-infected HepG2-hNTCP-C4 cells and primary human hepatocytes, leading to inhibition of viral RNA, HBsAg, and HBeAg production (EC50=0.64-1.52 uM).AB-506 demonstrated activity across HBV genotypes A-H and maintains antiviral activity against nucleostide analog-resistant variants in vitro.AB-506 showed an 8 to 20-fold increase in EC50 values against L30F, L37Q, and I105T substitutions.AB-506 exhibits good oral bioavailability, systemic exposure, and higher liver to plasma ratios in rodents. |
| Name | AB-506 |
|---|
| Description | AB-506 is a small-molecule inhibitor targeting HBV core protein, inhibits viral replication in vitro (IC50=77 nM).AB-506 binds to HBV core protein, accelerates capsid assembly and inhibits HBV pgRNA encapsidation.AB-506 blocks cccDNA establishment in HBV-infected HepG2-hNTCP-C4 cells and primary human hepatocytes, leading to inhibition of viral RNA, HBsAg, and HBeAg production (EC50=0.64-1.52 uM).AB-506 demonstrated activity across HBV genotypes A-H and maintains antiviral activity against nucleostide analog-resistant variants in vitro.AB-506 showed an 8 to 20-fold increase in EC50 values against L30F, L37Q, and I105T substitutions.AB-506 exhibits good oral bioavailability, systemic exposure, and higher liver to plasma ratios in rodents. |
|---|---|
| References | 1. Nagraj Mani, et al. Antiviral Res. 2022 Jan;197:105211. |
| Molecular Formula | C21H18ClF2N5O3 |
|---|---|
| Molecular Weight | 461.854 |